Oncolytics Biotech Inc. (ONCY)

[onco_investor]

Following up on the Rapamycin preclinical studies. Rapamycin is manufactured by Wyeth under the trade name Sirolimus and is an immunosupressant used currently as a transplant anti-rejection drug.

http://en.wikipedia.org/wiki/Rapamycin

Dr Handev shows that Reovirus is synergistic with another compound besides the paclitaxel/carboplatin, docetaxel, and gemcitibine combos already known (Cyclophosphamide is another that is under study)

This broad activity potential makes for an interesting list of potential partners...

Bristol Meyers Squibb (paclitaxel),

APP Pharmaceuticals, Bedford Laboratories, Sicor (Teva), Hospira, Pharmachemie, Pliva, Sandoz, and Spectrum make Carboplatin.

Sanofi-Aventis (docetaxel),

Wyeth/Pfizer (Rapamycin)

are all possibilities. This list does not include GSK, Merck, Amgen, Eli Lilly or Abbott

The recently announced Phase II/III trial will be Reolysin/paclitaxel/carboplatin combination to treat Head and Neck cancers.

It is widely expected that a second Phase II/III trial will be for Sarcoma using a Reolysin/Docetaxel combination.

This to me signals that BMS and Sanofi are the two companies most likely to watch for potential partnership interest.

onco_investor